
|Videos|August 12, 2014
Deciding Between Hormone Therapies in Patients With ER+/PR+ Tumors
Author(s)Ragene Rivera, MD
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
Advertisement
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
This segment is a part of our Case-Based Peer Perspectives.View the case details > >
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































